Matthew Hamilton Rosenberg’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Matthew Hamilton Rosenberg’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-13	Closed	-$1.5K	–	970
2023 Q3	$1.5K	Hold	13	–	–	﹤0.01%	767
2023 Q2	$1.34K	Hold	13	–	–	﹤0.01%	773
2023 Q1	$1.42K	Hold	13	–	–	﹤0.01%	802
2022 Q4	$1.48K	Hold	13	–	–	﹤0.01%	792
2022 Q3	$1K	Buy	+13	New	+$908	﹤0.01%	853

Other funds holding HZNP

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

VWA

Valued Wealth Advisors Holladay, Utah $247M AUM 21.93% 1-Year Est. Return

FSWA

Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return

BCMLT

Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Matthew Hamilton Rosenberg's HZNP Position: Q4 2023 in Review

Matthew Hamilton Rosenberg sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 13 shares — an estimated $1.5K sold.

Matthew Hamilton Rosenberg first reported a position in HZNP in Q3 2022 and held it in 5 quarters. The position peaked at $1.5K in Q3 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

Matthew Hamilton Rosenberg reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
Matthew Hamilton Rosenberg sold 13 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $1.5K.
Matthew Hamilton Rosenberg first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2022 and held it in 5 quarters.
Matthew Hamilton Rosenberg's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $1.5K in Q3 2023.
6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Matthew Hamilton Rosenberg's 13F filing for Q4 2023, filed 16 Jan 2024.